Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 23541-50-6 | Product Number: D4532
Daunorubicin Hydrochloride
×
Purity: >98.0%(N)
Synonyms:
- Hydroxydaunorubicin Hydrochloride
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 20MG |
€42.00
|
1 | ≥100 |
|
|
| 100MG |
€144.00
|
4 | ≥60 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | D4532 |
Purity / Analysis Method 
|
>98.0%(N) |
| Molecular Formula / Molecular Weight | C__2__7H__2__9NO__1__0·HCl = 563.98 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Hygroscopic,Heat Sensitive |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image), 20MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 23541-50-6 |
| Related CAS RN
|
20830-81-3 |
| Reaxys Registry Number | 4229221 |
| PubChem Substance ID | 253661912 |
| Merck Index (14) | 2832 |
| MDL Number | MFCD04974507 |
Specifications
| Appearance | Orange to Red powder to crystal |
| Purity(HPLC) | min. 96.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 %(calcd.on dried substance) |
| Specific rotation [a]20/D | +250 to +275 deg(C=0.15, MeOH) |
| Drying loss | max. 7.5 % |
Properties (reference)
| Melting Point | 167 °C(dec.) |
| Specific Rotation | 260° (C=0.15,MeOH) |
| Maximum Absorption Wavelength | 477 nm (H__2O) |
| Solubility in water | Soluble |
| Solubility (soluble in) | Methanol |
| Solubility (insoluble in) | Chloroform, Ether, Benzene |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. H317 : May cause an allergic skin reaction. H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled. H341 : Suspected of causing genetic defects. H351 : Suspected of causing cancer. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P261 : Avoid breathing dust. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P342 + P311 : If experiencing respiratory symptoms: Call a POISON CENTER/doctor. P304 + P340 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. |
Related Laws:
| EC Number | 245-723-4 |
| RTECS# | HB7878000 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| HS Number | 2941900000 |
Application
Adeno-associated virus vector transduction enhancer
Daunorubicin exhibits enhancement of adeno-associated virus transduction.1)
References
- 1) Identification and validation of small molecules that enhance recombinant adeno-associated virus transduction following high-throughput screens
Application
Daunorubicin Hydrochloride: An Anthracycline Antitumor Antibiotic
Daunorubicin Hydrochloride, an anthracycline antitumor antibiotic, was first isolated from fermentation broths of Streptomyces peucetius in 1967. Daunorubicin interacts with DNA by intercalation that causes disruption of transcription and replication. Daunorubicin also forms a complex with DNA and the enzyme topoisomerase II which is essential enzyme for DNA replication. The complexation hinders religation and leads to tumor cell apoptosis. Daunorubicin is mainly used for acute myeloid leukemia. (The product is for research purpose only.)
References
- Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals
- Biosynthetic studies of daunorubicin and tetracenomycin C (a review)
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin (a review)
- Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity (a review)
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs (a review)
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.